Experimental treatment strategies in primary cutaneous T-cell lymphomas

Sima Rozati, Youn H. Kim

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review Cutaneous T-cell lymphoma (CTCL) comprises a heterogeneous group of malignancies derived from skin-homing or resident T cells. Effective treatments are limited, thus new therapies are in development to address the unmet medical need. Recent findings Recent studies uncovering the genetic alteration in cutaneous T-cell lymphoma have enhanced our understanding of the importance of the T-cell activation/survival pathways, dysregulated immune system, and the relevance of chromatin modification in the pathogenesis of CTCL. New advances in cancer immunomodulation such as with PD1/PD-L1 inhibitors and novel targeted antitumor therapies such as brentuximab vedotin and mogamulizumab as well as potential combination strategies are promising for improving clinical efficacy with manageable toxicity profile. Summary All these new therapeutic approaches have resulted in broadening the treatment landscape and a potential paradigm shift in the management of CTCL.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalCurrent opinion in oncology
Volume28
Issue number2
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Keywords

  • cancer immunotherapy
  • cutaneous T-cell lymphoma
  • targeted cancer therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Experimental treatment strategies in primary cutaneous T-cell lymphomas'. Together they form a unique fingerprint.

Cite this